- Record: found
- Abstract: found
- Article: found
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
Kristian Reich ,
April W. Armstrong ,
Peter Foley ,
Michael Song ,
Yasmine Wasfi ,
Bruce Randazzo ,
Shu Li ,
Y.-K. Shen ,
Kenneth B. Gordon
March 2017
March 2017
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Phase II data suggested that guselkumab, an anti-interleukin-23 monoclonal antibody,
was efficacious in psoriasis.